Got a Medical Question? Ask a Doctor Online!
It is true. Suppressive therapy led to a significant reduction in overall acquisition of genital HSV-2 infection in the uninfected partner (1.9 versus 3.6 percent). Valacyclovir use was also associated with fewer days of viral shedding (2.9 versus 10.8 percent of days) and fewer recurrences of genital herpes (0.11 versus 0.40 per month) in the infected source partner.